Cytokinetics to Hold Annual Meeting of Stockholders
(Thomson Reuters ONE) -
South San Francisco, CA., May 15, 2013 - Cytokinetics, Incorporated (Nasdaq:
CYTK) announced today that its Annual Meeting of Stockholders will be held on
Tuesday, May 22, 2013 at 1:30 PM Pacific Time at the Embassy Suites Hotel,
located at 250 Gateway Boulevard in South San Francisco, CA. Robert I. Blum,
President and Chief Executive Officer, is scheduled to present an overview of
Cytokinetics' performance.
Interested parties may access the live audio webcast of this presentation and
replay by visiting the Investor Relations section of the Cytokinetics website at
www.cytokinetics.com. The live conference call may also be accessed by dialing
(866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078
(international) and typing in the passcode 11891010. The webcast will be
available via Cytokinetics' website for one week following the event. The
replay of the audiocast will be available via telephone from May 22, 2013 at
2:30 PM Pacific Time until May 29, 2013 by dialing (855) 859-2056 (United States
and Canada) or (404) 537-3406 (international) and typing in the passcode
11891010.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics' lead drug candidate from its cardiac muscle
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment of heart failure. Amgen Inc. holds an exclusive
license worldwide (excluding Japan) to develop and commercialize omecamtiv
mecarbil and related compounds, subject to Cytokinetics' specified development
and commercialization participation rights. Cytokinetics is independently
developing tirasemtiv and CK-2127107, both fast skeletal muscle activators, as
potential treatments for diseases and medical conditions associated with aging,
muscle wasting or neuromuscular dysfunction. Tirasemtiv is currently the subject
of a Phase II clinical trials program and has been granted orphan drug
designation and fast track status by the U.S. Food and Drug Administration and
orphan medicinal product designation by the European Medicines Agency for the
potential treatment of amyotrophic lateral sclerosis, a debilitating disease of
neuromuscular impairment in which treatment with tirasemtiv produced potentially
clinically relevant pharmacodynamic effects in Phase II trials. All of these
drug candidates have arisen from Cytokinetics' muscle biology focused research
activities and are directed towards the cytoskeleton. The cytoskeleton is a
complex biological infrastructure that plays a fundamental role within every
human cell. Additional information about Cytokinetics can be obtained at
www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking statements,
and claims the protection of the Act's safe harbor for forward-looking
statements. Examples of such statements include, but are not limited to,
statements relating to planned presentations, and the properties and potential
benefits of Cytokinetics' drug candidates and potential drug candidates. Such
statements are based on management's current expectations, but actual results
may differ materially due to various risks and uncertainties, including, but not
limited to, potential difficulties or delays in the development, testing,
regulatory approval and production of Cytokinetics' drug candidates and
potential drug candidates that could slow or prevent clinical development or
product approval, including risks that current and past results of clinical
trials or preclinical studies may not be indicative of future clinical trials
results and that Cytokinetics' drug candidates and potential drug candidates may
have unexpected adverse side effects or inadequate therapeutic efficacy. For
further information regarding these and other risks related to Cytokinetics'
business, investors should consult Cytokinetics' filings with the Securities and
Exchange Commission.
Contact:
Cytokinetics, Incorporated
Joanna L. Goldstein (Investors & Media)
(650) 624-3000
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Cytokinetics, Inc. via Thomson Reuters ONE
[HUG#1702385]
Unternehmensinformation / Kurzprofil:
Datum: 15.05.2013 - 22:00 Uhr
Sprache: Deutsch
News-ID 260648
Anzahl Zeichen: 5425
contact information:
Town:
SOUTH SAN FRANCISCO
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 143 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cytokinetics to Hold Annual Meeting of Stockholders"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytokinetics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
